208 related articles for article (PubMed ID: 19264695)
1. Rosuvastatin in patients with elevated C-reactive protein.
Gibbons RJ
N Engl J Med; 2009 Mar; 360(10):1038; author reply 1041-2. PubMed ID: 19264695
[No Abstract] [Full Text] [Related]
2. Rosuvastatin in patients with elevated C-reactive protein.
Jenny-Avital ER
N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271275
[No Abstract] [Full Text] [Related]
3. Another look at the results of the JUPITER trial.
Kappagoda CT; Amsterdam EA
Am J Cardiol; 2009 Dec; 104(11):1603-5. PubMed ID: 19932800
[TBL] [Abstract][Full Text] [Related]
4. Rosuvastatin in patients with elevated C-reactive protein.
Pierard LA
N Engl J Med; 2009 Mar; 360(10):1040; author reply 1041-2. PubMed ID: 19271277
[No Abstract] [Full Text] [Related]
5. Rosuvastatin in patients with elevated C-reactive protein.
Koller MT; Bucher HC; Steyerberg EW
N Engl J Med; 2009 Mar; 360(10):1041; author reply 1041-2. PubMed ID: 19271276
[No Abstract] [Full Text] [Related]
6. Rosuvastatin in patients with elevated C-reactive protein.
Chan PS; Nallamothu BK; Hayward RA
N Engl J Med; 2009 Mar; 360(10):1039; author reply 1041-2. PubMed ID: 19271273
[No Abstract] [Full Text] [Related]
7. [JUPITER study about rosuvastatin and risk of cardiovascular disease. Unclear consequences for the guideline].
Lubsen J
Ned Tijdschr Geneeskd; 2009 Feb; 153(6):216-7. PubMed ID: 19271438
[No Abstract] [Full Text] [Related]
8. [JUPITER no support of changed guidelines for cardiovascular prevention. Moderate absolute risk reduction and uncertain long term effects].
Håkansson J
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1460-1. PubMed ID: 19579433
[No Abstract] [Full Text] [Related]
9. [JUPITER study (2). For now no reason to give statins to more people].
Koopmans RP
Ned Tijdschr Geneeskd; 2009 Feb; 153(6):218-9. PubMed ID: 19271439
[No Abstract] [Full Text] [Related]
10. JUPITER study highlights value of anti-inflammatory action of rosuvastatin.
Cardiovasc J Afr; 2009; 20(3):211. PubMed ID: 19575096
[No Abstract] [Full Text] [Related]
11. [Less vascular risk with rosuvastatin in elevated CRP].
Bredie B
Ned Tijdschr Geneeskd; 2009 Feb; 153(6):245. PubMed ID: 19271446
[No Abstract] [Full Text] [Related]
12. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
Ridker PM;
Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
[No Abstract] [Full Text] [Related]
13. Low-risk older patients (50 years and older) with raised high-sensitivity CRP (hs-CRP) benefit from rosuvastatin therapy: the JUPITER study.
Cardiovasc J Afr; 2008; 19(6):332-4, discussion 335. PubMed ID: 19104734
[No Abstract] [Full Text] [Related]
14. [JUPITER can yield paradigmatic shift in the prevention of cardiovascular disease. Focus on inflammation as a risk factor].
Olsson AG
Lakartidningen; 2009 May 20-Jun 2; 106(21-22):1471-5. PubMed ID: 19579435
[No Abstract] [Full Text] [Related]
15. [JUPITER study, more reason to give statins as preventive measure - commentary].
Narkiewicz K
Kardiol Pol; 2009 Mar; 67(3):346-7. PubMed ID: 19469067
[No Abstract] [Full Text] [Related]
16. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
17. [Statin cuts cardiovascular risk in half].
Einecke D
MMW Fortschr Med; 2008 Dec; 150(49-50):12-3. PubMed ID: 19133364
[No Abstract] [Full Text] [Related]
18. Letter by Vos et al regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
Vos E; Rose CP; Biron P
Circulation; 2010 Dec; 122(23):e576; author reply e577. PubMed ID: 21135369
[No Abstract] [Full Text] [Related]
19. Letter by Wells and Eisenberg regarding article, "Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials".
Wells MT; Eisenberg T
Circulation; 2010 Dec; 122(23):e575; author reply e577. PubMed ID: 21135368
[No Abstract] [Full Text] [Related]
20. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
Kones R
Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
